A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment
Shukui Qin, Zhi-Gang Ren, Zhiqiang Meng et al. · Annals of Oncology · 2018
Cited by 28 works. doi:10.1093/annonc/mdy424.029